Skip to main content
. 2017 Mar 29;8(19):31959–31976. doi: 10.18632/oncotarget.16657

Figure 6. Treatment with Vidaza® enhances the immune recognition mediated by NKG2D-NKG2DL engagement.

Figure 6

NKL cells were co-incubated with C1R-MICA transfectants at the indicated E:T ratios (1:1 and 2:1) in a cell lysis assay, in the presence of sera obtained before and after treatment with Vidaza® from two independent AML patients. Values are the mean ± SEM of the percentage of specific lysis from three independent experiments. * versus control and p < 0.05; * versus control and p < 0.01 # versus pre-Vidaza® sera and p < 0.05.